Meningococcal Vaccines Market Size

Meningococcal Vaccines Market Size

Meningococcal Vaccines Market size was valued to be USD 4.3 billion in 2023 and is expected to register over 6.5% CAGR from 2024 to 2032. The market's significant growth is primarily driven by the rising prevalence of meningitis worldwide. For instance, according to the Centres for Disease Control and Prevention (CDC), there are approximately 1.2 million cases of bacterial meningitis worldwide each year.

To get key market trends

  Download Free Sample

The high morbidity and mortality associated with meningitis is different parts of the globe highlights the importance of vaccination as a preventive measure. In addition, areas with higher risk of disease transmission, such as healthcare facilities require mandatory meningococcal vaccination for individuals as it can lead to outbreaks in these specific demographics. Moreover, rising immunization programs, growing awareness about the disease, and increasing R&D activities concerning to meningococcal vaccines are expected to fuel the market growth during the forecast period.

Meningococcal vaccines are vaccines designed to protect individuals from infections caused by the bacterium Neisseria meningitidis, commonly referred to as meningococcus. Neisseria meningitidis is a leading cause of bacterial meningitis, which is a serious inflammation of the protective membranes covering the brain and spinal cord. Meningococcal vaccines stimulate the immune system to produce an immune response against the bacterium, preventing infection and its potentially severe and life-threatening consequences.